Literature DB >> 15730862

Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.

Christina Nilsson1, Johanna Forsman, Zuzana Hassan, Manuchehr Abedi-Valugerdi, Carmel O'Connor, Hernan Concha, Monika Jansson, Moustapha Hassan.   

Abstract

OBJECTIVE: The present study was designed to investigate the influence of the administration sequence of busulphan (Bu) and cyclophosphamide (Cy) during conditioning regimen on myeloablative and immunosuppressive effects and on engraftment.
METHODS: Female Balb/C mice were treated with either Bu-Cy or Cy-Bu (assigned order of administration). Bu was administered as 8.75 mg/kg/day x 4 and Cy as 100 mg/kg/day x 2. The control consisted of untreated animals. Bone marrow and spleen were harvested during the conditioning regimen and for up to 19 days after treatment. Colony-forming unit granulocyte macrophage assay was performed on marrow cells. Immunological analyses were performed using spleen cells. Liver status was determined using aspartate amino transferase (AST), alanine amino transferase (ALT), and bilirubin. Animals assigned for engraftment study were conditioned as above and transplanted using sca-1 cells from male Balb/C donors. Engraftment was followed using fluorescence in situ hybridization up to 30 days posttransplantation.
RESULTS: No significant difference in myeloablative effect was observed between treatments. Immunosuppressive activity expressed as CD3+/CD19+ and CD4+/CD8+ was also similar. Levels of cytokines interleukin 2, tumor necrosis factor alpha, and interferon gamma at the end of the conditioning regimen were lower in the Cy-Bu group, while liver enzymes were higher after the Bu-Cy regimen. Engraftment in bone marrow was reached faster within the first 20 days after conditioning with Cy-Bu compared to Bu-Cy. However, no difference in chimerism was observed at 30 days.
CONCLUSION: Cy-Bu treatment resulted in lower levels of cytokines, faster bone marrow engraftment, and lower values of liver enzymes compared to Bu-Cy regimen, which may benefit stem cell transplantation outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15730862     DOI: 10.1016/j.exphem.2004.12.003

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  6 in total

1.  Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment.

Authors:  Yasuyuki Arai; Uimook Choi; Cristina I Corsino; Sherry M Koontz; Masaki Tajima; Colin L Sweeney; Mary A Black; Steven A Feldman; Mary C Dinauer; Harry L Malech
Journal:  Mol Ther       Date:  2018-03-10       Impact factor: 11.454

2.  Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration.

Authors:  M E Dourthe; N Ternès; D Gajda; A Paci; C Dufour; E Benhamou; D Valteau-Couanet
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

3.  Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.

Authors:  Andrew R Rezvani; Jeannine S McCune; Barry E Storer; Ami Batchelder; Aiko Kida; H Joachim Deeg; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-10       Impact factor: 5.742

4.  Establishment and characterization of a new squamous cell carcinoma cell line, TMUU-08, derived from human bladder cancer.

Authors:  Choichiro Ozu; Hisashi Takeuchi; Kazuhito Matsushita; Yutaka Horiguchi; Kazunori Namiki; Kunihiko Yoshioka; Takeshi Nagai; Masaaki Tachibana
Journal:  Hum Cell       Date:  2009-02       Impact factor: 4.174

5.  Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.

Authors:  Mitchell E Horwitz; Ashley Morris; Cristina Gasparetto; Keith Sullivan; Gwynn Long; John Chute; David Rizzieri; Jackie McPherson; Nelson Chao
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

6.  Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.

Authors:  Claire Seydoux; Michael Medinger; Sabine Gerull; Joerg Halter; Dominik Heim; Yves Chalandon; Stavroula Masouridi Levrat; Urs Schanz; Gayathri Nair; Marc Ansari; Patrick Simon; Jakob R Passweg; Nathan Cantoni
Journal:  Ann Hematol       Date:  2020-10-23       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.